ESMO Conference Coverage
Featured Articles
(STAT Plus/Pharmalot) Oct 23, 2018 - What would you say if a cancer patient could be given a lower dose of a pricey treatment that was not only equally effective, but could also save a bundle of money? That’s the proposition being advanced by some leading oncologists, who are promoting what they call value-based prescribing, which...
Read Article
(Xconomy National) Oct 23, 2018 - The European Society for Medical Oncology is wrapping up its annual conference today, replete with clinical data from cancer’s front lines. We’ve sorted the headlines into a few big categories: immunotherapy combinations, breast cancer, lung cancer, the growing class of drugs called PARP inhibitors,...
Read Article
Latest Articles
October 23, 2018
October 23, 2018
October 23, 2018
October 23, 2018
October 23, 2018
October 23, 2018
October 23, 2018
October 23, 2018
View More
News Commentary
Editor Image
01 Oct, 2019 | by H. Jack West, MD
The impact of the CheckMate-227 trial remains to be seen. While it was positive...
View Comment
Editor Image
01 Oct, 2019 | by H. Jack West, MD
An important result that should satisfy the holdouts who were waiting on a...
View Comment
View More
OBR Blog
By: Stephanie Hawthorne, Ph.D., Senior Director, Clinical & Scientific Assessment, Kantar Health and Tari Awipi,... Read more
September 28, 2015
By: Stephanie Hawthorne, Ph.D., Senior Director, Clinical & Scientific Assessment, Kantar Health and Len Kusdra,... Read more
September 28, 2015

OBR Tweets

Jan 25
Daniel Catenacci, MD, of @UChicagoMed elaborates on the outcomes of the JAVELIN 100 study presented at ASCO GI 2020… https://t.co/SLFXcH9XHW

Jan 25
Manish Shah, MD, of @WeillCornell on the role of Cyramza in the treatment of gastric and esophageal cancers #GI20 https://t.co/83LT4SouTG

Jan 25
Daniel Catenacci, MD, of @UChicagoMed discusses margetuximab in the treatment of esophageal and gastric cancer #GI20 https://t.co/bKgtxzm0tl

Jan 25
Manish Shah, MD, of @WeillCornell regarding the use of liquid biopsy to diagnose and treat GI cancers #GI20 https://t.co/PgJcHQr2IZ

Jan 25
Sam Klempner, MD, of @harvardmed explains how circulating tumor DNA can be used to help determine therapy #GI20 https://t.co/xZwsm7PSW6

Jan 25
Hani Babiker, MD, of @UAZCancer elaborates on tumor treatment fields applying to GI malignancies #GI20 https://t.co/g8OENPsK7Y

Jan 25
Hani Babiker, MD, of @UAZCancer describes the setting of FDA approval on tumor treatment fields #GI20 https://t.co/Ytzc1MwAGM

Jan 25
Ahmed Kaseb, MD, of @MDAndersonNews on combining cabozantinib with checkpoint inhibitors for treatment of HCC #GI20 https://t.co/dd7RbGGru5

Jan 25
Ahmed Kaseb, MD, @MDAndersonNews on survival outcomes in the IMBRAVE 150 phase 3 study #GI20 https://t.co/3nSZN4yceY

Jan 25
Nevena Damjanov, MD, of @PennMedicine on impressions of the study of cabozantinib with in HCC patients #GI20 https://t.co/75BJaoY6je